Search

Your search keyword '"Salice, Marco"' showing total 26 results
Start Over Author "Salice, Marco"
26 results on '"Salice, Marco"'

2. COVID-19 in IBD: The experience of a single tertiary IBD center

Author

Rizzello, Fernando, Calabrese, Carlo, Salice, Marco, Calandrini, Lucia, Privitera, Hana, Melotti, Laura, Peruzzi, Giulia, Dussias, Nikolas, Belluzzi, Andrea, Scaioli, Eleonora, Decorato, Anastasio, Siniscalchi, Antonio, Filippone, Eleonora, Laureti, Silvio, Rottoli, Matteo, Poggioli, Gilberto, and Gionchetti, Paolo

Published
2021
Full Text
View/download PDF

6. Signatures of disease outcome severity in the intestinal fungal and bacterial microbiome of COVID-19 patients

Author

Rizzello, Fernando, primary, Viciani, Elisa, additional, Gionchetti, Paolo, additional, Filippone, Eleonora, additional, Imbesi, Veronica, additional, Melotti, Laura, additional, Dussias, Nikolas Konstantine, additional, Salice, Marco, additional, Santacroce, Barbara, additional, Padella, Antonella, additional, Velichevskaya, Alena, additional, Marcante, Andrea, additional, and Castagnetti, Andrea, additional

Published
2024
Full Text
View/download PDF

17. Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients

Author

Bertolini, Elena, primary, Macchioni, Pierluigi, additional, Rizzello, Fernando, additional, Salice, Marco, additional, Vukatana, Gentiana, additional, Sandri, Gilda, additional, Bertani, Angela, additional, Ciancio, Giovanni, additional, Govoni, Marcello, additional, Zelante, Angelo, additional, Malavolta, Nazzarena, additional, Beltrami, Marina, additional, and Salvarani, Carlo, additional

Published
2020
Full Text
View/download PDF

19. Timing and protocols of clinical and endoscopic surveillance of Barrett's esophagus

Author

Calabrese Carlo, Salice Marco, Pagano Nico, Manta Raffaele, Rizzello Fernando, Giuseppe Galloro, and Calabrese Carlo, Salice Marco, Pagano Nico, Manta Raffaele, Rizzello Fernando

Subjects
Barrett, Management, Treatment, digestive system diseases
Abstract

Barrett’s esophagus (BE) is a premalignant lesion in which normal squamous epi- thelium of the esophagus is replaced by metaplastic columnar epithelium of any histological subtype [1]. Several guidelines for diagnosing and managing BE have been published; however, they differ significantly among and within countries [1–3]. Only few large well-designed trials have been conducted so far [4–6].

Published
2018

24. Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?

Author

Paolo Gionchetti, L. Calandrini, Marta Mazza, Marco Salice, Fernando Rizzello, Carlo Calabrese, Massimo Campieri, Hana Privitera Hrustemovic, A. Calafiore, Poggioli Gilberto, and Rizzello fernando, salice marco, calabrese carlo, mazza marta, calafiore andrea, calandrini lucia, privitera hrustemovic hana, campieri massimo, gionchetti paolo

Subjects
Splenic flexure, medicine.medical_specialty, Pancolitis, business.industry, medicine.medical_treatment, IBD, Rectum, Disease, medicine.disease, Ulcerative colitis, Gastroenterology, digestive system diseases, Ulceratiove Coliti, Treatment, medicine.anatomical_structure, Internal medicine, medicine, Colitis, medicine.symptom, business, Proctitis, Colectomy
Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease which involves the colonic mucosa continuously starting from the rectum and progressively involving the entire colon. Its etiology is still unknown, although numerous studies have clarified the inflammatory mechanisms involved in the pathogenesis, allowing the development of new targeted drugs. Correct medical treatment requires the evaluation of disease extension, activity and behavior [1]. The Montreal classification allows extent to be defined into three subgroups: proctitis (when the inflammation is limited to the rectum), left-sided colitis (distal to the splenic flexure), and extensive or pancolitis (proximal to the splenic flexure) [2]. Drug formulation is chosen based on the disease extent: suppositories for proctitis, enemas for left-sided colitis and tablets for extensive colitis. Furthermore, patients with extensive colitis have a higher risk of colectomy or of developing colorectal...

Published
2019
Full Text
View/download PDF

25. The safety of beclomethasone dipropionate in the treatment of ulcerative colitis

Author

Carlo Calabrese, Fernando Rizzello, Marco Salice, A. Calafiore, Marta Mazza, Paolo Gionchetti, Massimo Campieri, Rizzello, Fernando, Mazza, Marta, Salice, Marco, Calabrese, Carlo, Calafiore, Andrea, Campieri, Massimo, and Gionchetti, Paolo

Subjects
safety, Drug, medicine.medical_specialty, medicine.drug_class, media_common.quotation_subject, Administration, Topical, adverse event, Anti-Inflammatory Agents, Administration, Oral, Placebo, Inflammatory bowel disease, Gastroenterology, ulcerative coliti, 03 medical and health sciences, chemistry.chemical_compound, Glucocorticoid, 0302 clinical medicine, Mesalazine, Internal medicine, medicine, Humans, Pharmacology (medical), Adverse effect, Mesalamine, Glucocorticoids, media_common, business.industry, steroid, Beclomethasone, General Medicine, respiratory system, medicine.disease, Ulcerative colitis, Algorithm, Anti-Inflammatory Agent, beclomethasone dipropionate, chemistry, Mechanism of action, 030220 oncology & carcinogenesis, Corticosteroid, 030211 gastroenterology & hepatology, Colitis, Ulcerative, medicine.symptom, business, Algorithms, Human
Abstract

Introduction: Beclomethasone dipropionate (BDP) is a second-generation corticosteroid that uses novel drug technologies to ensure colonic targeting and potentially reducing systemic corticosteroid concentrations. It is approved for treatment of patients with mild-to-moderate ulcerative colitis (UC) who do not respond to mesalazine. The gut-selective mechanism of action has the potential to improve the safety profile of BDP compared with other conventional corticosteroids. Areas covered: We reviewed the mechanism of action, efficacy, and safety of BDP in the treatment of UC. The positioning of BDP in management algorithms is also discussed. Expert opinion: The highly selective mechanism of action of BDP restricts the steroid-related side effects. BDP is efficacious in the treatment of active UC. Topical formulation is the first choice in distal UC, while oral formulation is used in patients with an extensive involvement of the colon. The rates of adverse events (AE), serious AEs, and steroid-related side-effects are similar to placebo and mesalamine and slightly inferior to traditional corticosteroids.

Published
2018

26. Is CMV DNAemia an early marker of CMV colitis in patients with active ulcerative colitis?

Author

Melotti L, Rinaldi M, Salice M, Dussias NK, Vanigli N, Calabrese C, Scaioli E, Gabrielli L, Lazzarotto T, Rosini F, Viale P, Gionchetti P, Giannella M, and Rizzello F

Subjects
Humans, Female, Male, Adult, Retrospective Studies, Middle Aged, Risk Factors, Prognosis, Aged, Colectomy, Biomarkers blood, Colitis virology, Colitis diagnosis, Cytomegalovirus Infections virology, Cytomegalovirus Infections diagnosis, Cytomegalovirus Infections complications, Colitis, Ulcerative virology, Colitis, Ulcerative complications, Cytomegalovirus genetics, Cytomegalovirus isolation & purification, DNA, Viral genetics, DNA, Viral blood
Abstract

Cytomegalovirus (CMV) colitis is a serious concern worsening the prognosis of patients with ulcerative colitis (UC). We aimed to assess risk factors and prognostic impact of CMV colitis in patients with moderate-to-severe UC flare. We conducted a retrospective, observational, single-center study. Consecutive adult patients hospitalized for moderate-to-severe UC from January 2020 to June 2023 were included. The primary endpoint was a diagnosis of CMV-colitis according to immunohistochemistry on tissue biopsies. The secondary endpoint was the need for colectomy within 30 days. Overall, 135 patients were included. CMV colitis was diagnosed in n = 37 (27.4%): n = 19 (51.4%) endoscopically, the remaining on surgical specimens. Of them, n = 23 (62.2%) had positive CMV-DNAemia with a median value of 1,008 cp/mL (interquartile range 318-2,980). Differences between the two groups (CMV colitis vs non-CMV) included age (60 vs 41 years, P = 0.004), Charlson Comorbidity Index (1 vs 0, P = 0.003), steroid refractoriness (86.5% vs 62.2%, P = 0.007), and positive CMV-DNAemia (62.2% vs 10.1%, P < 0.001). At multivariable analysis, steroid-refractory disease, Charlson Comorbidity Index, and CMV-DNAemia were associated with CMV colitis. Overall, n = 54 (39.7%) patients underwent colectomy, and this was significantly more common in patients with CMV colitis vs non-CMV group (54.1% vs 34.4%, P = 0.049). Kaplan-Meier showed that antiviral therapy seems to have a relevant impact on colectomy ( P < 0.001). CMV-DNA blood detection is independently associated with CMV-positive refractory UC. Since CMV colitis may increase the risk of colectomy and antiviral treatment seems to reduce such risk, prospective studies are needed to confirm the role of CMV-DNA blood detection to early diagnose CMV colitis., Importance: Cytomegalovirus (CMV) colonic reactivation worsens the prognosis of patients with active ulcerative colitis. Blood CMV-DNA reactivation is strongly associated with CMV colitis. Prompt diagnosis and treatment of CMV colitis can avoid surgery in most cases., Competing Interests: P.G. received honoraria from Janssen, Abbvie, Pfizer, Celgene, Takeda, Ferring, MSD, Amgen, and Alfa-Sigma, and he participated in a company sponsored speaker's bureau of Abbvie, Janssen, Takeda, FGerring, MSD, Sofar, and Chiesi. F.R. received honoraria from Janssen, Abbvie, Pfizer, Takeda, Ferring, and MSD, and he participated in a company sponsored speaker's bureau of Abbvie, Jansen, Takeda, Ferring, MSD, Sofar, and Chiesi. The other authors have no conflicts of interest to declare.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results